New Urinary Test for Acute Pancreatitis
New Urinary Test for Acute Pancreatitis
ABSTRACT & COMMENTARY
Synopsis: A new urinary test for detecting acute pancreatitis is better than blood or urinary amylase.
Source: Kemppainen EA, et al. N Engl J Med 1997;336: 1788-1793.
Severe acute pancreatitis is a common condition, especially at urban public hospitals. The differential diagnosis is large. The use of amylase and lipase blood and/or urine assays have sub-optimal test characteristics with frequent false-positives and -negatives. Contract-enhanced computer tomography is currently the most accurate, non-surgical test, but it is financially and labor intensive. A fast, accurate, and low-cost test would be a major advance.
Finnish investigators have reported their prospective evaluation of a new urinary assay that measures trypsinogen-2. Trypsinogen is a pancreatic proteinase with two isoenzymes. A small amount of the enzyme escapes from the biliary tree into the circulation where it is subsequently filtered by the renal glomeruli. The investigators developed a rapid dipstick test for detecting elevated trypsinogen-2 concentrations in urine and prospectively evaluated its utility at two large Finnish hospitals.
A total of 500 consecutive adult patients with acute abdominal pain were studied. No one was excluded. All patients had blood and urine amylase tests as well as trypsinogen-2 levels. Selected patients had abdominal CT. Acute pancreatitis and its severity were defined by international consensus criteria that did not include amylase levels. Fifty-three patients were diagnosed with acute pancreatitis; 50/53 (94% sensitivity) had a positive urinary trypsinogen-2 (> 50 ng/mL), and 21/447 had a false-positive test (95% specificity). The amylase testing at various thresholds never had a sensitivity exceeding 85%.
COMMENT BY BRUCE E. HILLNER, MD
This is a straightforward, uncomplicated evaluation of a new diagnostic test with no exclusions, dropouts, or obvious confounders. If this assay, when it becomes commercially available, is priced reasonably, it should randomly diffuse into routine practice.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.